Psilocybin

Alamut/Bibliothek/1964_smart_2335_1.pdf. Treatment of alcoholism using p... [J Psychoactive Drugs. 1998 Oct-Dec. Regulatory Toxicology and Pharmacology - Harm potential of magic mushroom use: A review. Abstract In 2007, the Minister of Health of the Netherlands requested the CAM (Coordination point Assessment and Monitoring new drugs) to assess the overall risk of magic mushrooms.

The present paper is an updated redraft of the review, written to support the assessment by CAM experts. It summarizes the literature on physical or psychological dependence, acute and chronic toxicity, risk for public health and criminal aspects related to the consumption of magic mushrooms. In the Netherlands, the prevalence of magic mushroom use was declining since 2000 (last year prevalence of 6.3% in 2000 to 2.9% in 2005), and further declined after possession and use became illegal in December 2008. The CAM concluded that the physical and psychological dependence potential of magic mushrooms was low, that acute toxicity was moderate, chronic toxicity low and public health and criminal aspects negligible.

Keywords Magic mushrooms; Illicit drugs; Risk assessment; Adverse effects; Recreational drugs. 8] - Web of Science. WEB OF Science Your ideal single research destination to explore the citation universe across subjects and around the world.

Web of Science provides you access to the most reliable, integrated, multidisciplinary research connected through linked content citation metrics from multiple sources within a single interface. And since Web of Science adheres to a strict evaluation process, you can be assured only the most influential, relevant, and credible information is included - allowing you to uncover your next big idea faster. Web of Science connects the entire search and discover process through: Premier Multidisciplinary Content Emerging Trends Subject Specific Content Regional Content Research Data Analysis Tools.

Pharmaceutica Acta Helvetiae - Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Abstract.

Neuropharmacology - Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes. Abstract Affinities of drugs for 21 indolealkylamine derivatives, some with putative hallucinogenic activity, were determined at 5-HT1A, 5-HT2A and 5-HT2B recognition sites, using radioligand competition studies.

Nearly all of the derivatives displayed greatest potency for the 5-HT2A receptor, labelled by in the cortex of the rat. Most derivatives displayed 2–10 times lower affinity at the HT2B receptor labelled by [3H]ketanserin in bovine cortex. The pharmacology of psilocybin. [Addict Biol. 2002. Serotonin. Serotonin /ˌsɛrəˈtoʊnɨn/ or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter.

Biochemically derived from tryptophan, serotonin is primarily found in the gastrointestinal tract (GI tract), platelets, and the central nervous system (CNS) of animals, including humans. It is popularly thought to be a contributor to feelings of well-being and happiness.[6] Serotonin secreted from the enterochromaffin cells eventually finds its way out of tissues into the blood. There, it is actively taken up by blood platelets, which store it. Neuropharmacology - Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes.

1 Department of Neurology, Stanford University School of Medicine, Stanford, California 94305, U.S.A.2 Institute of Organic Chemistry, Syntex Research, 3401 Hillview Avenue, Palo Alto, California 94304, U.S.A.

Accepted 9 August 1989, Available online 25 November 2002 Choose an option to locate/access this article: Check if you have access through your login credentials or your institution. Magic mushrooms ban becomes law. A law banning magic mushrooms and making them a class A drug has come into force.

The Drugs Act 2005 ends the situation in which fresh magic mushrooms were legal but those which were dried or prepared for use were not. Sellers have condemned the move, saying mushrooms are not harmful and accusing ministers of a knee-jerk reaction. Dr. Leary's Concord Prison Experiment: A 34 Year Follow-Up Study. Dr.

Leary's Concord Prison Experiment: A 34 Year Follow-Up Study pp. 10-18. Psilocybin, Senate Race Highlight Harvard Year. President Pusey announced on May 27 that the Corporation had terminated the appointment of Richard Alpert as assistant professor of Clinical Psychology and of Education for giving halluginogenic drugs to an undergraduate in violation of an agreement with the University.

The dismissal, the first in Pusey's ten years at Harvard, climaxed more than a year of off-and-on controversey over the work of Alpert and an associate, Timothy Leary, Lecturer on Clinical Psychology, with psilocybin. (Leary was relieved of his teaching duties by the Corporation, and his salary suspended, for absenting himself from the University without permission.) Psilocybin had first become an issue in March, 1962, when members of the Center for Research in Personality charged, at a closed meeting, that drug experiments were being conducted in an un-scientific and irresponsible manner. The issue revived on November 26, when Dean Monro and Dr. Seeking the Magic Mushroom. Background[edit] Huautla de Jiménez Wasson first became interested in mycology during his honeymoon in the Catskill Mountains in 1927.[7] His new wife, Valentina Pavlovna Wasson, a native of Moscow, Russia, was identifying and collecting mushrooms in the forest, having been brought up with an appreciation for the species.

Wasson was disgusted. "Like all good Anglo-Saxons, I knew nothing about the fungal world and felt that the less I knew about those putrid, treacherous excrescences the better. Ac.els-cdn.com/S0379073898001686/1-s2.0-S0379073898001686-main.pdf?_tid=a0042cb8-1c3a-11e2-8808-00000aab0f26&acdnat=1350905069_790652dd3591657f9ac6a4c578ba799e.

Forensic Science International - Detection of psilocin in body fluids. Www.maps.org/research/psilo/psilo_ib.pdf. Psilocin. Psilocin (also known as 4-OH-DMT, psilocine, psilocyn, or psilotsin), is a substituted tryptamine alkaloid and a serotonergic psychedelic substance. It is present in most psychedelic mushrooms together with its phosphorylated counterpart psilocybin. Psilocin is a Schedule I drug under the Convention on Psychotropic Substances.[2] The mind-altering effects of psilocin are highly variable and subjective and resemble those of LSD and DMT. Chemistry[edit] Psilocin and its phosphorylated cousin, psilocybin, were first isolated and named in 1958 by Swiss chemist Albert Hofmann. Hofmann obtained the chemicals from laboratory-grown specimens of the entheogenic mushroom Psilocybe mexicana.

Psilocin is relatively unstable in solution due to its phenolic hydroxy (-OH) group. Structural analogs[edit] Pharmacology[edit] Psilocin is the pharmacologically active agent in the body after ingestion of psilocybin or some species of psychedelic mushrooms. Psilocin's half-life ranges from 1 to 3 hours.[1] V. 19 1959-62 - Botanical Museum leaflets, Harvard University. Psilocybin mushroom.